Last reviewed · How we verify
Meibomianitis
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Garamycin · Merck & Co.
- Tobi · Novartis
- Vantobra · Pfizer
- Gentamicin · Merck & Co.
- Nebcin · University Hospital, Lille
- Prelone · Generic (originally Schering)
- prednisolon · Hannover Medical School
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Meibomianitis patent landscape — cliff calendar, originator estates, attackable patents
- Meibomianitis treatment landscape brief
- Meibomianitis treatment updates RSS
Frequently asked questions about Meibomianitis
What drugs treat Meibomianitis?
Tracked treatments include Ramycin, Garamycin, Tobi, Vantobra, Gentamicin, Nebcin, Prelone, prednisolon.
What is the treatment for Meibomianitis?
Standard treatment for Meibomianitis includes Ramycin, Garamycin, Tobi, Vantobra, Gentamicin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Meibomianitis patent cliff · Meibomianitis CI report
- Treatment: Ramycin
- Treatment: Garamycin · Merck & Co.
- Treatment: Tobi · Novartis
- Treatment: Vantobra · Pfizer
- Treatment: Gentamicin · Merck & Co.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing